GLP-1 Medications and Sleep Apnea: What the Research Shows
Tirzepatide became the first FDA-approved drug for obstructive sleep apnea in 2024. Learn what clinical trials reveal about GLP-1 medications and OSA.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on April 2, 2026
Our medical review process ensures clinical accuracy and patient safety.
GLP-1 Medications and Sleep Apnea: A New Frontier in Treatment
Obstructive sleep apnea affects an estimated 936 million adults worldwide, yet until December 2024 there was no FDA-approved pharmacological treatment for the condition. That changed when the FDA approved tirzepatide (Zepbound) — a dual GLP-1/GIP receptor agonist — specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. The approval marked a turning point, confirming what clinical trials had been suggesting for years: GLP-1 receptor agonists can meaningfully improve sleep apnea, not just as a side effect of weight loss, but potentially through independent mechanisms.
Evidence: "Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide significantly reduced the apnea-hypopnea index, body weight, hypoxic burden, and systolic blood pressure and improved sleep-related patient-reported outcomes." — Malhotra A, et al. N Engl J Med. 2024. DOI: 10.1056/NEJMoa2404881
This article breaks down the clinical evidence, the mechanisms behind the benefit, who qualifies for treatment, and what limitations remain.
The Link Between Obesity, OSA, and GLP-1 Medications
Obstructive sleep apnea is caused by repeated partial or complete collapse of the upper airway during sleep. In people with obesity, excess adipose tissue — especially around the neck and pharynx — narrows the airway and increases the likelihood of collapse. The standard of care remains continuous positive airway pressure (CPAP), but adherence is notoriously poor, with studies showing that 30–50% of patients abandon CPAP within the first year.
GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) produce significant weight loss — typically 15–22% of body weight in clinical trials — which directly reduces upper-airway fat deposits. But weight loss alone does not fully account for the observed improvements in sleep apnea severity. Researchers have identified at least two additional pathways:
- Anti-inflammatory effects: GLP-1 RAs reduce circulating levels of high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation. Inflammation of upper-airway muscles is thought to contribute to collapsibility.
- Neuromuscular and central effects: GLP-1 receptors are expressed in the brainstem regions that regulate upper-airway muscle tone. Animal studies suggest direct GLP-1 signaling may stabilize these muscles during sleep, independent of weight change.
SURMOUNT-OSA: The Landmark Trial
The most rigorous evidence comes from the SURMOUNT-OSA trials, two parallel phase-3 randomized controlled trials published in the New England Journal of Medicine in June 2024 (DOI: 10.1056/NEJMoa2404881).
Trial Design
469 adults with moderate-to-severe OSA and obesity (BMI ≥30) were enrolled across 60 sites in nine countries. Participants were divided into two groups:
- Trial 1: Participants unable or unwilling to use PAP therapy
- Trial 2: Participants already receiving PAP therapy at baseline
Both groups were randomized to weekly tirzepatide (10 mg or 15 mg, maximum tolerated dose) or placebo for 52 weeks.
Key Results
| Outcome | Tirzepatide | Placebo | Change vs Placebo |
|---|---|---|---|
| AHI reduction (Trial 1) | −25.3 events/hr | −5.3 events/hr | −20.0 events/hr |
| AHI reduction (Trial 2) | −29.3 events/hr | −5.5 events/hr | −23.8 events/hr |
| Disease resolution rate (Trial 1) | 43.0% | — | — |
| Disease resolution rate (Trial 2) | 51.5% | — | — |
| Mean body weight reduction | ~18–20% | ~2% | — |
| hsCRP reduction | Significant | Minimal | — |
The primary endpoint — change in apnea-hypopnea index (AHI) — showed reductions of 62–63% with tirzepatide compared to placebo. Nearly half of all participants on the drug achieved disease resolution or mild non-symptomatic OSA by week 52.
Evidence: "The mean (±SD) change in the AHI at week 52 was −25.3±30.6 events per hour with tirzepatide as compared with −5.3±20.5 events per hour with placebo (estimated treatment difference, −20.1 events per hour; 95% CI, −27.9 to −12.3)." — Malhotra A, et al. N Engl J Med. 2024. DOI: 10.1056/NEJMoa2404881
What Meta-Analyses Show About GLP-1 RAs as a Class
While tirzepatide has the most robust data, semaglutide and liraglutide have also been evaluated. A 2025 systematic review and meta-analysis published in Sleep Medicine (PubMed ID: 39978242) pooled randomized controlled trial data from multiple GLP-1 receptor agonists in patients without type 2 diabetes.
Evidence: "GLP-1 RA treatment was associated with a significant reduction in apnea-hypopnea index compared to placebo, with a weighted mean difference of −16.6 events per hour (95% CI: −27.9 to −5.3)." — Systematic review, Sleep Medicine. 2025. DOI: 10.1016/j.sleep.2025.02.010
A separate meta-analysis and systematic review published in early 2025 (Taylor & Francis / Tandfonline, DOI: 10.1080/20018525.2025.2484048) confirmed that across studies, GLP-1 RAs significantly improved AHI, body weight, and systolic blood pressure, while adverse events were manageable and consistent with the known safety profile of this drug class.
Comparing GLP-1 Agents for OSA
| Medication | AHI Reduction | Weight Loss | OSA-specific Approval |
|---|---|---|---|
| Tirzepatide (Zepbound) | Up to 29.3 events/hr | ~18–20% | Yes (FDA, Dec 2024) |
| Semaglutide (Wegovy) | ~15–20 events/hr (estimated) | ~15–17% | No (off-label) |
| Liraglutide (Saxenda) | ~10–12 events/hr (estimated) | ~8–10% | No (off-label) |
Data for semaglutide in OSA come from smaller trials and sub-analyses; a dedicated clinical trial (NCT07281196) is currently underway.
FDA Approval: What It Means for Patients
On December 20, 2024, the FDA approved Zepbound (tirzepatide) for the treatment of moderate-to-severe OSA in adults with obesity, making it the first pharmacological agent ever approved for this indication.
Evidence: "FDA has approved Zepbound (tirzepatide) injection for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity." — U.S. Food and Drug Administration. December 2024. FDA Press Announcement
The indication is specifically for adults with:
- Moderate-to-severe OSA (AHI ≥15 events/hour)
- Obesity (BMI ≥30)
It is approved as an adjunct to lifestyle modification and can be used alongside CPAP therapy or as an alternative for patients who cannot tolerate CPAP.
The drug received Fast Track, Priority Review, and Breakthrough Therapy designations for this indication — a signal of how unmet the clinical need had been.
Who Should Consider GLP-1 Therapy for Sleep Apnea?
GLP-1 receptor agonists for OSA are appropriate for a specific patient profile. A clinician would typically consider this approach when:
- The patient has confirmed moderate-to-severe OSA plus obesity
- CPAP adherence is poor or the patient refuses PAP therapy
- The patient has comorbidities that would also benefit from GLP-1 therapy (type 2 diabetes, cardiovascular disease, metabolic syndrome)
- The patient is motivated to combine pharmacotherapy with lifestyle change
They are not a replacement for CPAP in all patients. Clinical practice guidelines from the American Academy of Sleep Medicine still endorse PAP therapy as the first-line treatment for moderate-to-severe OSA. Tirzepatide's role is as an adjunct or alternative in appropriate patients.
Patients on GLP-1 medications for weight loss who also have OSA should discuss formal sleep testing with their physician, as their AHI may improve enough to reduce or eliminate CPAP requirements.
For a broader look at how GLP-1 drugs affect other organ systems, see our article on GLP-1 cardiovascular benefits.
Safety and Side Effects
The safety profile of tirzepatide in the SURMOUNT-OSA trials was consistent with previous tirzepatide trials. The most common adverse events were gastrointestinal:
- Nausea: ~20–25% of tirzepatide participants
- Vomiting: ~10–12%
- Diarrhea: ~15–18%
- Constipation: ~10%
Most GI effects were mild-to-moderate and occurred during dose escalation, resolving over time. Serious adverse events were low and comparable to placebo.
The 2025 meta-analysis noted that GLP-1 RAs were associated with a higher overall frequency of adverse events compared to placebo (OR 1.62; 95% CI: 1.16 to 2.24), but this was driven primarily by GI side effects and did not affect discontinuation rates significantly in the trial context.
For a full overview of what to expect, see our guide to GLP-1 side effects.
Limitations and Open Questions
Several important questions remain unresolved:
- Long-term durability: Most trials ran for 52 weeks. Whether AHI improvements persist over multiple years — and whether OSA returns after drug discontinuation — is not yet established.
- Mechanism independence from weight loss: Although tirzepatide's cardiovascular and inflammatory benefits suggest mechanisms beyond fat loss, it remains difficult to separate the direct airway effect from weight-mediated improvement in human trials.
- Role of semaglutide: Semaglutide is widely used off-label in patients who have OSA, but the evidence base is thinner. Dedicated RCTs are needed.
- Non-obese OSA patients: Approximately 30% of OSA patients are not obese. GLP-1 medications are unlikely to be beneficial in this subgroup and carry risks without clear benefit.
Key Takeaways
- Tirzepatide (Zepbound) received FDA approval in December 2024 as the first medication ever approved specifically for obstructive sleep apnea.
- The SURMOUNT-OSA trial demonstrated AHI reductions of 25–29 events/hour with tirzepatide vs 5 events/hour with placebo, with ~43–51% of participants achieving disease resolution.
- Meta-analyses confirm that GLP-1 receptor agonists as a class reduce AHI by approximately 16–17 events/hour on average.
- The mechanism includes both weight loss-mediated airway decompression and potential direct anti-inflammatory and neuromuscular effects.
- Tirzepatide for OSA is indicated as an adjunct to lifestyle modification in adults with obesity and moderate-to-severe OSA. It can be used with or without CPAP.
- GI side effects are the main tolerability concern, consistent with the broader GLP-1 class profile.
References
Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. DOI: 10.1056/NEJMoa2404881
Kumbhare S, et al. Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials. Sleep Medicine. 2025;128:15-25. DOI: 10.1016/j.sleep.2025.02.010 PubMed
Turk M, et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials. ERJ Open Research. 2025. DOI: 10.1080/20018525.2025.2484048
Alimoradi Z, et al. FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea. JAMA. 2025;333(6):474. PubMed
U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024. FDA
Last updated: 2026-04-02 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.